REG - Theracryf PLC - Annual Financial Report and Notice of AGM

TheracryfAnnouncement

21/06/2024 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240621:nRSU3868Ta&default-theme=true

RNS Number : 3868T  Theracryf PLC  21 June 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Posting of Annual Report and Notice of AGM

Alderley Park, UK - 21 June 2024: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on oncology and neuropsychiatry, announces
that its Annual Report and Accounts for the year ended 31 March 2024 have been
posted to shareholders and are now available on the Company website.

Additionally, the Company's AGM will take place on at 2.30 p.m. on Thursday 18
July 2024 in the Block 11 Lecture Theatre, Alderley Park Conference Centre,
Cheshire, United Kingdom, SK10 4TG.

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Instinctif Partners                                         +44 207 457 2020
 Melanie Toyne-Sewell / Jack Kincade
theracryf@Instinctif.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or
clinical proof of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a number of
industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFIFEDRRILFIS